These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 2585019

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT.
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [Abstract] [Full Text] [Related]

  • 4. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L.
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [Abstract] [Full Text] [Related]

  • 5. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA, Hum GJ, Sheehan WW, Ryden VM, Bateman JR.
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [Abstract] [Full Text] [Related]

  • 6. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.
    Biti GP, Cimino G, Cartoni C, Magrini SM, Anselmo AP, Enrici RM, Bellesi GP, Bosi A, Papa G, Giannarelli D.
    J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677
    [Abstract] [Full Text] [Related]

  • 7. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD, Chauvenet AR.
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [Abstract] [Full Text] [Related]

  • 8. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL, Duffey PL, DeVita VT, Wiernik PH, Hubbard SM, Phares JC, Bastian AW, Jaffe ES, Young RC.
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [Abstract] [Full Text] [Related]

  • 9. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
    Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P.
    J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, EORTC-GELA H8 Trial.
    N Engl J Med; 2007 Nov 08; 357(19):1916-27. PubMed ID: 17989384
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL, Terrier-Lacombe MJ, Bey P, Bertrand Y, Rubie H.
    J Clin Oncol; 1992 Oct 08; 10(10):1602-8. PubMed ID: 1383434
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B.
    J Clin Oncol; 1997 Apr 08; 15(4):1638-45. PubMed ID: 9193364
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of the early response to chemotherapy in high-risk stages II and III Hodgkin's disease.
    Levis A, Vitolo U, Ciocca Vasino MA, Cametti G, Urgesi A, Bertini M, Canta M, Monetti U, Bosio C, Jayme A.
    Cancer; 1987 Oct 15; 60(8):1713-9. PubMed ID: 3651998
    [Abstract] [Full Text] [Related]

  • 18. A new combination chemotherapy for recurrent Hodgkin's lymphoma.
    Rahim MA, Sarma SK, Ahmed Q.
    Bangladesh Med Res Counc Bull; 1982 Dec 15; 8(2):63-7. PubMed ID: 6897860
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N, Hagemeister F, Velasquez W, Cabanillas F.
    J Clin Oncol; 1983 Jul 15; 1(7):432-9. PubMed ID: 6199478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.